keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29236294/acute-myeloid-leukemia-and-myelodysplastic-syndrome-after-adjuvant-chemotherapy-a-population-based-study-among-older-breast-cancer-patients
#1
Aron S Rosenstock, Jiangong Niu, Sharon H Giordano, Hui Zhao, Antonio C Wolff, Mariana Chavez-MacGregor
BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. METHODS: Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases...
December 13, 2017: Cancer
https://www.readbyqxmd.com/read/29236174/oncotype-dx%C3%A2-in-breast-cancer-patients-clinical-experience-outcome-and-follow-up-a-case-control-study
#2
Michelle G Rath, Lorenz Uhlmann, Marita Fiedler, Joerg Heil, Michael Golatta, Christine Dinkic, Andre Hennigs, Sarah Schott, Veronika Ernst, Thorsten Koch, Christof Sohn, Cosima Brucker, Joachim Rom
PURPOSE: Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4]...
December 13, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29235043/effects-of-physical-exercise-on-markers-of-inflammation-in-breast-cancer-patients-during-adjuvant-chemotherapy
#3
Jonna K van Vulpen, Martina E Schmidt, Miranda J Velthuis, Joachim Wiskemann, Andreas Schneeweiss, Roel C H Vermeulen, Nina Habermann, Cornelia M Ulrich, Petra H M Peeters, Elsken van der Wall, Anne M May, Karen Steindorf
PURPOSE: Exercise has been shown to reduce fatigue during cancer treatment. Hypothesized mechanisms include inflammatory pathways. Therefore, we investigated effects of exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy. METHODS: We pooled data from two randomized controlled exercise intervention trials with breast cancer patients during adjuvant chemotherapy (n = 130), which had previously shown beneficial effects of exercise on fatigue...
December 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29234591/reproductive-hormone-analyses-and-effects-of-adjuvant-zoledronic-acid-in-early-breast-cancer-an-azure-big-01-04-sub-study
#4
Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E Coleman
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29234362/chinese-herbal-medicine-as-an-adjunctive-therapy-ameliorated-the-incidence-of-chronic-hepatitis-in-patients-with-breast-cancer-a-nationwide-population-based-cohort-study
#5
Kuo-Chin Huang, Hung-Rong Yen, Jen-Huai Chiang, Yuan-Chih Su, Mao-Feng Sun, Hen-Hong Chang, Sheng-Teng Huang
We conducted a National Health Insurance Research Database-based Taiwanese nationwide population-based cohort study to evaluate whether Chinese herbal medicine (CHM) treatment decreased the incidence of chronic hepatitis in breast cancer patients receiving chemotherapy and/or radiotherapy. A total of 81171 patients were diagnosed with breast cancer within the defined study period. After randomly equal matching, data from 13856 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence and therapeutic potential of CHM in patients with breast cancer...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29234306/body-mass-index-influences-the-prognostic-impact-of-combined-nuclear-insulin-receptor-and-estrogen-receptor-expression-in-primary-breast-cancer
#6
Sofie Björner, Ann H Rosendahl, Maria Simonsson, Andrea Markkula, Karin Jirström, Signe Borgquist, Carsten Rose, Christian Ingvar, Helena Jernström
The prognostic importance of tumor-specific nuclear insulin receptor (InsR) expression in breast cancer is unclear, while membrane and cytoplasmic localization of InsR is better characterized. The insulin signaling network is influenced by obesity and may interact with the estrogen receptor α (ERα) signaling. The purpose was to investigate the interplay between nuclear InsR, ER, body mass index (BMI), and prognosis. Tumor-specific expression of nuclear InsR was evaluated by immunohistochemistry in tissue microarrays from 900 patients with primary invasive breast cancer without preoperative treatment, included in a population-based cohort in Sweden (2002-2012) in relation to prognosis...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29234255/influence-of-orally-administered-probiotic-lactobacillus-strains-on-vaginal-microbiota-in-women-with-breast-cancer-during-chemotherapy-a-randomized-placebo-controlled-double-blinded-pilot-study
#7
Julian Marschalek, Alex Farr, Marie-Louise Marschalek, Konrad J Domig, Wolfgang Kneifel, Christian F Singer, Herbert Kiss, Ljubomir Petricevic
Background: Due to chemotherapy and estrogen deprivation therapy, genitourinary syndrome of menopause is a common condition in breast cancer patients. We aimed to determine the effect of an orally administered Lactobacillus preparation on the vaginal microbiota in breast cancer patients. Methods: Postmenopausal breast cancer patients receiving chemotherapy, with vaginal atrophy and an intermediate vaginal microbiota (Nugent score 4-6), were either randomized to the intervention group receiving probiotic capsules of 4 Lactobacillus species or to the control group receiving placebo twice daily for 2 weeks...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234253/evaluation-of-sentinel-lymph-node-biopsy-and-axillary-lymph-node-dissection-for-breast-cancer-treatment-concepts-a-retrospective-study-of-1-214-breast-cancer-patients
#8
Roland G Stein, Roland Fricker, Thomas Rink, Hartmut Fitz, Sebastian Blasius, Joachim Diessner, Sebastian F M Häusler, Tanja N Stüber, Victoria Andreas, Achim Wöckel, Thomas Müller
Background: Most breast cancer patients require lumpectomy with axillary sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). The ACOSOG Z0011-trial failed to detect significant effects of ALND on disease-free and overall survival among patients with limited sentinel lymph node (SLN) metastases. Intense dose-dense chemotherapy and supraclavicular fossa radiation (SFR) are indicated for patients with extensive axillary metastases. In this multicentered study, we investigated the relevance of ALND after positive SLNB to determine adequate adjuvant therapy...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234252/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy-a-subgroup-analysis-of-hormone-receptor-positive-her2-negative-breast-cancer
#9
Hans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter Fasching, Michael Untch, Oliver Hoffmann, Max Bulsara, Jayant Vaidya, Cornelia Liedtke
Introduction: In a previous study our group showed a beneficial effect of targeted intraoperative radiotherapy (TARGIT-IORT) as an intraoperative boost on overall survival after neoadjuvant chemotherapy (NACT) compared to an external boost (EBRT). In this study we present the results of a detailed subgroup analysis of the hormone receptor (HR)-positive HER2-negative patients. Methods: In this cohort study involving 46 patients with HR-positive HER2-negative breast cancer after NACT, we compared the outcomes of 21 patients who received an IORT boost to those of 25 patients treated with an EBRT boost...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29233925/a20-regulates-the-dna-damage-response-and-mediates-tumor-cell-resistance-to-dna-damaging-therapy
#10
Chuanzhen Yang, Weicheng Zang, Zefang Tang, Yapeng Ji, Ruidan Xu, Yongfeng Yang, Aiping Luo, Bin Hu, Zemin Zhang, Zhihua Liu, Xiaofeng Zheng
A competent DNA damage response (DDR) helps prevent cancer, but once cancer has arisen DDR can blunt the efficacy of chemotherapy and radiotherapy which cause lethal DNA breakage in cancer cells. Thus, blocking DDR may improve the efficacy of these modalities. Here we report a new DDR mechanism that interfaces with inflammatory signaling and might be blocked to improve anticancer outcomes. Specifically, we report that the ubiquitin-editing enzyme A20 binds and inhibits the E3 ubiquitin ligase RNF168, which is responsible for regulating histone H2A turnover critical for proper DNA repair...
December 12, 2017: Cancer Research
https://www.readbyqxmd.com/read/29233640/rapid-response-to-larotrectinib-loxo-101-in-an-adult-chemotherapy-naive-patients-with-advanced-triple-negative-secretory-breast-cancer-expressing-etv6-ntrk3-fusion
#11
Yosef Landman, Maya Ilouze, Simon Wein, Victoria Neiman, Rinat Yerushalmi, Maxim Yakimov, Nora Ku, Alexa B Schrock, Siraj Ali, Nir Peled
No abstract text is available yet for this article.
November 28, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29233615/diet-quality-inflammation-and-quality-of-life-in-breast-cancer-survivors-a-cross-sectional-analysis-of-pilot-study-data
#12
Tonya S Orchard, Rebecca R Andridge, Lisa D Yee, Maryam B Lustberg
BACKGROUND: Modifiable lifestyle factors, such as diet quality, could reduce inflammation and improve quality of life (QOL) in breast cancer survivors, but data are inconclusive. OBJECTIVE: To determine whether diet quality, as measured by Healthy Eating Index-2010 (HEI-2010) score, is associated with inflammation, health status, or functional outcomes affecting QOL in survivors of early-stage breast cancer. DESIGN: This is a cross-sectional, secondary analysis of baseline data collected from breast cancer survivors after completion of primary therapy and before random assignment to a pilot nutritional intervention aimed at reducing side effects of aromatase inhibitor treatment...
December 9, 2017: Journal of the Academy of Nutrition and Dietetics
https://www.readbyqxmd.com/read/29233559/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast-cancer-a-pooled-analysis-of-3771-patients-treated-with-neoadjuvant-therapy
#13
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang D Schmitt, Jens-Uwe Blohmer, Thomas Karn, Berit M Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiss, Arndt Hartmann, Aurelia Noske, Peter A Fasching, Christian Jackisch, Marion van Mackelenbergh, Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer. METHODS: Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group...
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233548/the-impact-of-actual-body-weight-based-chemotherapy-dosing-and-body-size-on-adverse-events-and-outcome-in-older-patients-with-breast-cancer-results-from-cancer-and-leukemia-group-b-calgb-trial-49907-alliance-a151436
#14
Vicki A Morrison, Linda McCall, Hyman B Muss, Aminah Jatoi, Harvey J Cohen, Constance T Cirrincione, Jennifer A Ligibel, Jacqueline M Lafky, Arti Hurria
OBJECTIVE: Actual weight-based (AWB) chemotherapy dosing is recommended for obese patients in the 2012 ASCO Clinical Practice Guideline. CALGB 49907, which utilized ABW-based adjuvant chemotherapy dosing, was a phase 3 trial in women age≥65years with early stage breast cancer, providing the opportunity to examine impact of such dosing on toxicities and outcome in older patients with breast cancer. MATERIALS AND METHODS: Adverse event data were available for 615 of 633 enrolled patients...
December 7, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29232804/lymphovascular-invasion-as-a-negative-prognostic-factor-for-triple-negative-breast-cancer-after-surgery
#15
Ki Jung Ahn, Jisun Park, Yunseon Choi
Purpose: This study aimed to evaluate the prognostic effects of lymphovascular invasion (LVI) in triple-negative breast cancer (TNBC) patients who underwent surgical resection. Materials and Methods: A total of 63 non-metastatic TNBC patients who underwent surgical resection were retrospectively investigated from 2007 to 2016 in Inje University Busan Paik Hospital. Pathological tests revealed that 12 patients (19.0%) had LVI. Approximately 61.9% (n = 39) of the patients' samples stained positive for p53...
December 15, 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/29232552/therapeutic-antibody-targeting-tumor-and-osteoblastic-niche-derived-jagged1-sensitizes-bone-metastasis-to-chemotherapy
#16
Hanqiu Zheng, Yangjin Bae, Sabine Kasimir-Bauer, Rebecca Tang, Jin Chen, Guangwen Ren, Min Yuan, Mark Esposito, Wenyang Li, Yong Wei, Minhong Shen, Lanjing Zhang, Nikolai Tupitsyn, Klaus Pantel, Chadwick King, Jan Sun, Jodi Moriguchi, Helen Toni Jun, Angela Coxon, Brendan Lee, Yibin Kang
Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells...
December 11, 2017: Cancer Cell
https://www.readbyqxmd.com/read/29232539/how-to-identify-and-manage-cognitive-dysfunction-after-breast-cancer-treatment
#17
Marie Lange, Florence Joly
Attention and memory dysfunction is a common complaint among patients with breast cancer that can be reported during and up to several years after treatment. It can negatively affect patients' quality of life and their ability to work. This phenomenon has mainly been studied in patients with breast cancer who are treated with adjuvant chemotherapy. Women describe concentration problems and difficulties with word finding, multitasking, or remembering new information, as well as more effort and time needed to accomplish these tasks...
December 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29231918/-systemic-treatment-of-early-breast-cancer-current-state-of-knowledge-after-the-conference-st-gallen-2017
#18
REVIEW
Tomasz Sarosiek
Breast cancer is the most commonly diagnosed malignancy in women around the globe. It is also the world's first cause of female deaths from cancer. With the introduction of screening programs in most developed countries, more and more cases of this cancer are diagnosed at local or localized stages, enabling radical treatment to be successful. At the same time, systemic treatment of early breast cancer is one of the most complex issues in clinical oncology. Because of the many prognostic factors that need to be taken into account when considering eligibility for treatment such as age, reproductive status (before or after menopause), type of cancer and severity of the disease, it is impossible to establish clear standards of conduct for many clinical situations...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29230663/advantages-with-prophylactic-peg-rhg-csf-versus-rhg-csf-in-breast-cancer-patients-receiving-multiple-cycles-of-myelosuppressive-chemotherapy-an-open-label-randomized-multicenter-phase-iii-study
#19
Jie Xie, Jun Cao, Jing-Fen Wang, Bai-Hong Zhang, Xiao-Hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-Dong Wu, Qiang Yao, Xiao-Chun Zhao, Wei-Dong Mao, Ai-Mei Jiang, Shao-Shui Chen, Shun-E Yang, Shu-Sen Wang, Jian-Hong Wang, Yue-Yin Pan, Bi-Yong Ren, Yan-Ju Chen, Li-Zhi Ouyang, Kai-Jian Lei, Jing-Hua Gao, Wen-He Huang, Zhan Huang, Tao Shou, Yan-Ling He, Jing Cheng, Yang Sun, Wei-Ming Li, Shu-de Cui, Xin Wang, Zhi-Guo Rao, Hu Ma, Wei Liu, Xue-Yong Wu, Wei-Xi Shen, Fei-Lin Cao, Ze-Min Xiao, Biao Wu, Shu-Yan Tian, Dong Meng, Peng Shen, Bi-Yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-Chun Hu
BACKGROUND: PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China's registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy. METHODS: In this open-label, randomized, multicenter phase 3 study, breast cancer patients (n = 569) were randomized to receive PEG-rhG-CSF 100 µg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 µg/kg/d after chemotherapy...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29230661/weak-circadian-rhythm-increases-neutropenia-risk-among-breast-cancer-patients-undergoing-adjuvant-chemotherapy
#20
Wentao Li, Carol Chi-Hei Kwok, Dominic Chun-Wan Chan, Feng Wang, Lap Ah Tse
PURPOSE: Severe neutropenia is a common dose-limiting side effect of adjuvant breast cancer chemotherapy. We aimed to test the hypothesis that weak circadian rhythm is associated with an increased risk of neutropenia using a cohort study. METHODS: We consecutively recruited 193 breast cancer patients who received adjuvant chemotherapy (5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel; doxorubicin and cyclophosphamide; docetaxel and cyclophosphamide)...
December 11, 2017: Breast Cancer Research and Treatment
keyword
keyword
40931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"